{"id":78531,"date":"2026-09-03T17:35:52","date_gmt":"2026-09-03T09:35:52","guid":{"rendered":"https:\/\/flcube.com\/?p=78531"},"modified":"2026-09-03T17:35:53","modified_gmt":"2026-09-03T09:35:53","slug":"pegbio-signs-rd-collaboration-with-sn-bioscience-to-pair-three-innovative-peptide-candidates-with-sna-long-acting-delivery-for-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78531","title":{"rendered":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>PegBio Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2565:HKG\">HKG: 2565<\/a>) announced that it has entered into a material transfer agreement (MTA) with South Korean biotechnology company <strong>SN BioScience, Inc.<\/strong> to conduct joint R&amp;D collaboration on three independently developed innovative <strong>peptide<\/strong> drug candidates for metabolic diseases. The collaboration will apply <strong>SN BioScience&#8217;s<\/strong> proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform to <strong>PegBio&#8217;s<\/strong> candidates \u2014 including APGP6 \u2014 evaluating whether next\u2011generation delivery technology can sharpen differentiation in an increasingly competitive metabolic space.<\/p>\n\n\n\n<h2 id=\"h-deal-terms-at-a-glance\" class=\"wp-block-heading\">Deal Terms at a Glance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>PegBio Co., Ltd.<\/strong> (HKG: 2565) and <strong>SN BioScience, Inc.<\/strong> (South Korea)<\/td><\/tr><tr><td>Structure<\/td><td>Material transfer agreement (MTA) for joint R&amp;D collaboration<\/td><\/tr><tr><td>Assets<\/td><td>Three independently developed innovative <strong>peptide<\/strong> drug candidates for metabolic diseases, including APGP6<\/td><\/tr><tr><td>Technology Applied<\/td><td><strong>SN BioScience&#8217;s<\/strong> proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform<\/td><\/tr><tr><td>Research Scope<\/td><td>In vivo performance, pharmacokinetic characteristics, and further development potential of candidate\u2011platform combinations<\/td><\/tr><tr><td>Follow\u2011On Options<\/td><td>Potential licensing, co\u2011development, commercialization, or other strategic collaboration if technical evaluation is favorable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-collaboration-profile-amp-strategic-logic\" class=\"wp-block-heading\">Collaboration Profile &amp; Strategic Logic<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PegBio&#8217;s Contribution:<\/strong> Three independently developed innovative <strong>peptide<\/strong> candidates targeting metabolic diseases, including lead program APGP6<\/li>\n\n\n\n<li><strong>SN BioScience&#8217;s Contribution:<\/strong> The proprietary SNA long\u2011acting drug delivery platform, designed to extend duration of action for therapeutic molecules<\/li>\n\n\n\n<li><strong>Joint Evaluation:<\/strong> The parties will assess in vivo performance, pharmacokinetics, and development potential of each candidate\u2011platform combination<\/li>\n\n\n\n<li><strong>Differentiation Thesis:<\/strong> Combining long\u2011acting delivery technologies with different molecules aims to enhance product differentiation in metabolic disease therapy, where dosing frequency is a key competitive lever<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Metabolic space momentum:<\/strong> The collaboration lands amid intense global interest in metabolic disease therapeutics, where long\u2011acting formulations are a decisive factor in patient adherence and market adoption<\/li>\n\n\n\n<li><strong>De\u2011risked structure:<\/strong> The MTA keeps the partnership at the technical evaluation stage, limiting commitment while preserving a clear pathway toward licensing, co\u2011development, or commercialization agreements<\/li>\n\n\n\n<li><strong>Cross\u2011border synergy:<\/strong> Pairing <strong>PegBio&#8217;s<\/strong> peptide discovery capabilities with <strong>SN BioScience&#8217;s<\/strong> Korean delivery\u2011technology platform reflects the growing trend of Asia\u2011to\u2011Asia biotech collaboration<\/li>\n\n\n\n<li><strong>Optionality for both sides:<\/strong> If technical compatibility is demonstrated, either party can negotiate definitive commercial terms separately \u2014 keeping upside open without premature lock\u2011in<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the research outcomes, technical compatibility, and potential follow\u2011on collaboration under the MTA. The research currently remains at the technical evaluation stage; any follow\u2011on collaboration structure and commercial terms will be separately negotiated and subject to definitive agreements. Actual results may differ materially due to scientific, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090201331_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090201331_c.\"><\/object><a id=\"wp-block-file--media-5a4f65ff-8560-470a-93f3-9a57996d9abc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090201331_c.pdf\">2026090201331_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090201331_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5a4f65ff-8560-470a-93f3-9a57996d9abc\"><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4078,2105,4922],"class_list":["post-78531","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2565","tag-pegbio","tag-sn-bioscienc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement (MTA) with South Korean biotechnology company SN BioScience, Inc. to conduct joint R&amp;D collaboration on three independently developed innovative peptide drug candidates for metabolic diseases. The collaboration will apply SN BioScience&#039;s proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform to PegBio&#039;s candidates \u2014 including APGP6 \u2014 evaluating whether next\u2011generation delivery technology can sharpen differentiation in an increasingly competitive metabolic space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78531\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78531\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T09:35:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T09:35:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases\",\"datePublished\":\"2026-09-03T09:35:52+00:00\",\"dateModified\":\"2026-09-03T09:35:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2565\",\"PegBio\",\"SN BioScienc\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78531#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78531\",\"name\":\"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-03T09:35:52+00:00\",\"dateModified\":\"2026-09-03T09:35:53+00:00\",\"description\":\"PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement (MTA) with South Korean biotechnology company SN BioScience, Inc. to conduct joint R&D collaboration on three independently developed innovative peptide drug candidates for metabolic diseases. The collaboration will apply SN BioScience's proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform to PegBio's candidates \u2014 including APGP6 \u2014 evaluating whether next\u2011generation delivery technology can sharpen differentiation in an increasingly competitive metabolic space.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78531\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78531#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement (MTA) with South Korean biotechnology company SN BioScience, Inc. to conduct joint R&D collaboration on three independently developed innovative peptide drug candidates for metabolic diseases. The collaboration will apply SN BioScience's proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform to PegBio's candidates \u2014 including APGP6 \u2014 evaluating whether next\u2011generation delivery technology can sharpen differentiation in an increasingly competitive metabolic space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78531","og_locale":"en_US","og_type":"article","og_title":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=78531","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-03T09:35:52+00:00","article_modified_time":"2026-09-03T09:35:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78531#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78531"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases","datePublished":"2026-09-03T09:35:52+00:00","dateModified":"2026-09-03T09:35:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78531"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2565","PegBio","SN BioScienc"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78531#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78531","url":"https:\/\/flcube.com\/?p=78531","name":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-03T09:35:52+00:00","dateModified":"2026-09-03T09:35:53+00:00","description":"PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement (MTA) with South Korean biotechnology company SN BioScience, Inc. to conduct joint R&D collaboration on three independently developed innovative peptide drug candidates for metabolic diseases. The collaboration will apply SN BioScience's proprietary Serinol Nucleic Acids (SNA) long\u2011acting drug delivery platform to PegBio's candidates \u2014 including APGP6 \u2014 evaluating whether next\u2011generation delivery technology can sharpen differentiation in an increasingly competitive metabolic space.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78531#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78531"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78531#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PegBio Signs R&amp;D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long\u2011Acting Delivery for Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78531"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78531\/revisions"}],"predecessor-version":[{"id":78534,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78531\/revisions\/78534"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}